- Trial phase
- Approved
- Time to market
- Already approved and marketed (FDA approval October 2020)
- Why 3/10
- Inmazeb is already FDA-approved and commercialized with no pending regulatory decision, pivotal readout, or label-expansion catalyst in the next 12 months. It is a tiny part of Regeneron's massive, diversified pipeline, the company generated ~$14.3B in 2025 revenue from Dupixent, Eylea, Libtayo, and other products. Per the impact score rubric, an approved drug with no upcoming binary catalyst scores 3-5, and given its negligible financial contribution to a large-cap biotech, a score of 3 is appropriate.
Inmazeb has no upcoming binary catalyst, it is already approved and commercialized via episodic government contracts. The October 26, 2026 BARDA extension (~$270M through 2031) is the most recent news, but this is a multi-year supply deal, not a stock-moving event. Watch for future Ebola outbreak-related procurement announcements or WHO guideline updates, but Inmazeb is too small a piece of Regeneron's ~$80B market cap to drive meaningful share-price moves on its own.
Price Chart
Executive Summary
Inmazeb (atoltivimab/maftivimab/odesivimab, aka REGN-EB3) is Regeneron's FDA-approved three-antibody cocktail for Ebola Zaire virus, approved in October 2020 as the first-ever FDA-approved Ebola treatment. It demonstrated a 33.5% 28-day mortality rate versus 51.3% for the control in the PALM trial. Revenue is episodic and government-contract-driven, Regeneron does not separately disclose Inmazeb sales, and it is a negligible contributor to the company's ~$14.3B annual revenue (dominated by Dupixent, Eylea, and Libtayo). On October 26, 2026, Regeneron announced a ~$270M BARDA contract extension through 2031 for U.S. government stockpiling. For a Regeneron investor, Inmazeb is a low-impact strategic asset with no upcoming binary catalyst.
How It Works
Inmazeb is a cocktail of three lab-made antibodies (atoltivimab, maftivimab, and odesivimab) that bind to the surface protein of the Ebola Zaire virus, blocking it from entering human cells and flagging the virus for destruction by the immune system. It is given as a single intravenous infusion.
Trial Status
Inmazeb was approved by the FDA in October 2020 based on the PALM trial (NCT03719586), a multi-center, open-label, randomized controlled trial conducted during the 2018-2019 Ebola outbreak in the Democratic Republic of Congo. The trial was stopped early at a pre-specified interim analysis when Inmazeb showed a significant reduction in 28-day mortality (33.5% vs 51.3% for the ZMapp control group, p=0.002). The label was updated in 2023 to include neonates born to infected mothers.
The Two-Sided Case
Upcoming Catalysts
- No upcoming binary catalyst, Inmazeb is already approved. Future catalysts would be limited to new government procurement contracts (e.g., BARDA extensions), WHO guideline updates, or outbreak-related emergency use requests, none of which are scheduled or predictable.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Regeneron Pharmaceuticals, Inc. Press Release REGN ·Originating report